Type 1 and 3 von Willebrand disease (VWD) represent the most frequent and rarest forms, respectively of the most common inherited bleeding disorder described in humans. Both conditions are quantitative traits with reductions of von Willebrand factor (VWF) being mild/moderate in type 1 VWD and severe in type 3 disease. In this research proposal, we will further pursue the pathogenesis of these conditions.
In Aim #1 of the project we will carry out studies to further examine the role of sequence variation in and around the VWF gene in the pathogenesis of type 1 and 3 VWD. These studies will determine the potential pathogenetic role of regulatory region variants, intronic variants and copy number variation.
Aim #2 of the project will involve a re-assessment of the association data presented in the recently published CHARGE genome-wide association study meta-analysis. These studies will be performed primarily to fine-map the original SNP associations described in the CHARGE meta-analysis.
Aims 3 and 4 will involve studies to address the finding of five novel pathogenetic candidates reported in the CHARGE GWAS report.
In Aim #3 we will perform studies to evaluate the role of two candidates identified in CHARGE that appear to have the potential to play a role in VWF biosynthesis, storage and/or secretion. These studies will involve a combination of cell biology and genetic approaches to determining the role of Syntaxin Binding Protein 5 (STXBP5) and Syntaxin 2 (STX2) in regulating VWF synthesis and release from cells. In parallel with the studies to evaluate normal STXBP5 and STX2 function, we will search for variants of these proteins in our type 1 and 3 VWD populations and will determine the influence of selected variants in the experimental systems that we have established. Finally, in Aim #4 we will use a similar combination of biology and genetics to investigate the influence of accelerated clearance of VWF by the receptors C-type lectin domain family 4 member M, Stabilin-2 and Scavenger receptor class A member 5. Again, after characterizing the role of the normal receptors in binding to and clearing VWF, we will evaluate the influence of variant forms of the receptors derived from a genetic search of our type 1 VWD patient cohorts.

Public Health Relevance

This research project addresses the genetic background of two inherited bleeding disorders, one, type 1 von Willebrand disease, that is the most common bleeding problem encountered in the general population, and the second, type 3 von Willebrand disease, a rare variant form of the condition. Both diseases result in chronic morbidities due to recurrent excessive mucocutaneous bleeding.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
2P01HL081588-06
Application #
8246618
Study Section
Heart, Lung, and Blood Initial Review Group (HLBP)
Project Start
Project End
Budget Start
2012-02-15
Budget End
2013-01-31
Support Year
6
Fiscal Year
2012
Total Cost
$343,976
Indirect Cost
$6,500
Name
Medical College of Wisconsin
Department
Type
DUNS #
937639060
City
Milwaukee
State
WI
Country
United States
Zip Code
53226
Flood, Veronica H; Abshire, Thomas C; Christopherson, Pamela A et al. (2018) Von Willebrand disease in the United States: perspective from the Zimmerman program. Ann Blood 3:
Mufti, Ahmad H; Ogiwara, Kenichi; Swystun, Laura L et al. (2018) The common VWF single nucleotide variants c.2365A>G and c.2385T>C modify VWF biosynthesis and clearance. Blood Adv 2:1585-1594
Jacobi, P M; Kanaji, S; Jakab, D et al. (2018) von Willebrand factor propeptide to antigen ratio identifies platelet activation and reduced von Willebrand factor survival phenotype in mice. J Thromb Haemost 16:546-554
Szederjesi, A; Baronciani, L; Budde, U et al. (2018) An international collaborative study to compare different von Willebrand factor glycoprotein Ib binding activity assays: the COMPASS-VWF study. J Thromb Haemost :
Selvam, Soundarya N; Casey, Lara J; Bowman, Mackenzie L et al. (2017) Abnormal angiogenesis in blood outgrowth endothelial cells derived from von Willebrand disease patients. Blood Coagul Fibrinolysis 28:521-533
Baumgartner, C K; Mattson, J G; Weiler, H et al. (2017) Targeting factor VIII expression to platelets for hemophilia A gene therapy does not induce an apparent thrombotic risk in mice. J Thromb Haemost 15:98-109
Selvam, Soundarya; James, Paula (2017) Angiodysplasia in von Willebrand Disease: Understanding the Clinical and Basic Science. Semin Thromb Hemost 43:572-580
Lorenz, Viola; Ramsey, Haley; Liu, Zhi-Jian et al. (2017) Developmental Stage-Specific Manifestations of Absent TPO/c-MPL Signalling in Newborn Mice. Thromb Haemost 117:2322-2333
Bowman, M L; Pluthero, F G; Tuttle, A et al. (2017) Discrepant platelet and plasma von Willebrand factor in von Willebrand disease patients with p.Pro2808Leufs*24. J Thromb Haemost 15:1403-1411
Doruelo, A L; Haberichter, S L; Christopherson, P A et al. (2017) Clinical and laboratory phenotype variability in type 2M von Willebrand disease. J Thromb Haemost 15:1559-1566

Showing the most recent 10 out of 120 publications